Dulaglutide
Weekly GLP-1 receptor agonist fused to an IgG4 Fc fragment; sold as Trulicity by Eli Lilly.
Appetite or glycemic effects within the first days; full effect accrues over weeks to months alongside titration.
Store the lyophilized powder refrigerated (2 to 8 C), or frozen for long-term storage, protected from light. After reconstitution with bacteriostatic water, keep refrigerated and use within about 4 weeks.
Clinical Evidence
What the literature says
Scientific Overview
Dulaglutide (Trulicity, Eli Lilly, FDA-approved 2014) is a GLP-1 analog covalently linked to a human IgG4 Fc fragment, giving a half-life of ~5 days. The REWIND trial demonstrated CV benefit in T2DM with and without established CVD. Less weight loss than semaglutide/tirzepatide but strong cardio-metabolic profile.
Citations (4)
- The GLP-1 Receptor Agonist Dulaglutide Attenuates Hepatic Steatosis in Obesity via a Weight-Independent MechanismPubMed
- Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 DiabetesPubMed
- Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: Exploratory analyses of AWARD‐11Review
- Assessment of Changes in Body Composition After 3 Months of Dulaglutide TreatmentReview
Research Guide
How users approach this compound
The following reflects patterns observed in research literature and community protocols. This is not medical advice and does not constitute a clinical recommendation.
Research Protocols
Common DosagesT2DM
“Titrate every 4 weeks”
Dosages listed are common research protocols found in peer-reviewed literature and clinical trials. Individual results and requirements may vary significantly in a research context.
Key Research Benefits
- Once-weekly dosing
- HbA1c reduction
- CV risk reduction (REWIND)
Potential Side Effects
Labs to monitor
Educational context only, not a testing mandate. Any bloodwork decisions belong with your clinician.
- HbA1c: Primary glycemic efficacy marker for incretin therapy.
- Fasting glucose: Tracks glycemic response and hypoglycemia risk in combination therapy.
- Lipid panel / ApoB: Incretin therapy commonly improves atherogenic lipids alongside weight loss.
Dose Calculator
Peptide Reconstitution Calculator
Total amount of peptide in the vial.
Volume of water used to mix.
Draw to this mark
or 0.30 mL on a U-100 syringe
Dulaglutide by goal
Read Dulaglutide's profile filtered through specific research goals.
Related Tools
Not medical advice
Information on DoseVault is for educational purposes only and is not a substitute for medical advice, diagnosis, or treatment from a qualified healthcare provider.